Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Beyond Meat Inc (BYND) vs 10X Genomics Inc (TXG) Price & Performance

Beyond Meat IncTrade
10X Genomics IncTrade

Price performance (Past 24H)

Key statistics

Beyond Meat Inc vs 10X Genomics Inc — how do they compare? Beyond Meat Inc trades at $0.4 (market cap $215.41M), while 10X Genomics Inc trades at $57.74 (market cap $7.61B). The key difference: 10X Genomics Inc is far larger — about 35.3× Beyond Meat Inc's market cap, and 10X Genomics Inc is trading nearer its 52-week high, Beyond Meat Inc nearer its low. Which is the better fit depends on your goals.

BYNDTXG
Market Cap
$215.41M$7.61B
Sector
Consumer StaplesHealth
52-Week High
$3.62$58.57
52-Week Low
$0.42$11.34
Enterprise Value
$455.69M$7.14B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Beyond Meat Inc

Beyond Meat (BYND) trades at $0.52, down 3.29% amid bearish technical signals and recent reverse stock split. The company shows mixed fundamentals with revenue declining from $419M in 2022 to $275M in 2025, though net income turned positive at $178M in 2025 with a 64.6% margin. Technical indicators show bearish momentum with moving averages signaling sell and ADX confirming strong downtrend, while RSI remains neutral. Recent news highlights stock collapse to all-time lows following the 30:1 reverse split announcement in August 2026.

Investment outlook remains highly risky with 57% analyst sell ratings and persistent cash burn from operations. While valuation ratios appear attractive (P/S 0.61, EV/EBITDA 1.28), declining revenue and negative operating cash flow (-$145M in 2025) challenge sustainability. The turnaround strategy focusing on international expansion faces execution risks amid competitive pressures and consumer demand uncertainties.

10X Genomics Inc

TXG trades at $58.57, up 12.57% in 24 hours, reflecting strong momentum. The stock is technically bullish with moving averages supporting the uptrend, though RSI levels suggest overbought conditions. Fundamentally, the company shows improving trends with Q2 2026 earnings beating estimates and revenue growth, yet remains unprofitable with a negative net income margin. Recent news highlights collaborations and acquisitions expanding its genomic capabilities.

Outlook is mixed; analyst consensus is neutral with a $46 price target below current levels, indicating caution despite recent beats. Key risks include sustained losses and competitive pressures, but operational cash flow growth and strategic expansions offer potential upside for patient investors focused on long-term biotech innovation.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Beyond Meat Inc

Beyond Meat is a provider of plant-based meats, such as burgers, sausage, ground beef, and chicken. Unlike other vegetarian products, Beyond Meat seeks to replicate the look, cook, and taste of meat, is targeted to omnivores and vegetarians alike, and is sold in the meat case. The products are widely available across the U.S. and Canada and in 83 additional countries as well. International revenue represented 31% of 2021 sales. The firm's products are available in retail stores and the food-service channel. In 2019, before the pandemic struck, sales were evenly split between these two channels, although mix stood at 70% retail/30% food service in 2021. We think the recovery from the crisis and new deals with McDonald's and Yum Brands will return food-service sales to nearly 50% in time.

Read more on BYND

About 10X Genomics Inc

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.

Read more on TXG